Global Medical REIT Inc . (NYSE:GMRE) recently disclosed its third-quarter 2023 earnings, focusing on robust portfolio performance despite a slight decrease in net income attributable to common shareholders. The real estate investment trust (REIT) reported a net income of $3.1 million, or $0.05 per share, compared to $8.1 million or $0.12 per share in Q3 2022. The company attributed the decline to increased interest costs, which also affected funds from operations (FFO) and adjusted funds from operations (AFFO).
Key takeaways from the earnings call include:
- Global Medical REIT sold a medical office building in South Carolina for $10.1 million, realizing a gain of $2.3 million. The company has generated over $80 million from three dispositions year-to-date.
- The company's portfolio consists of $1.4 billion in gross investments in real estate, boasting a 96.7% occupancy rate and a weighted average lease term of 5.7 years.
- The REIT maintains a leverage ratio of 44.2% and an unutilized borrowing capacity of $318 million.
- Global Medical REIT is actively engaging with potential sellers and anticipates resuming acquisition activity once market conditions normalize.
- Approximately one-third of the investment pipeline originates from new relationships.
- The company expects to maintain an occupancy rate of approximately 96.5% by the end of the year, retaining 80% of the expiring square footage and 86% of the related expiring annual base rent (ABR).
- The company has spent about $5.8 million on capital expenditures, projecting additional expenditures of $3 million on improvements.
- The company is targeting capitalization rates in the 8s to 9s range for acquisitions, emphasizing the accretiveness and quality of properties.
- Tenant performance remains solid, with no significant changes to the watchlist. The company reported an average lease escalator of 2.5%.
Global Medical REIT is optimistic about filling vacancies quickly in the future, owing to the increasing demand for incremental space. The company has not identified any compelling opportunities yet, but expects a continuous influx of deals into next year. The company's investment strategy primarily targets properties with less than three years of wall.
Despite the challenges, the company has no significant exposure to Genesis Care and expects no significant changes in the fourth quarter. The company's Board expressed confidence in maintaining the current dividend of $0.21 per share. They also noted that the reception to taking operating partnership (OP) units as part of transactions is unpredictable and depends on various factors, including state context and the estate planning of physicians.
InvestingPro Insights
In light of the recent earnings report, InvestingPro's real-time data and tips offer a comprehensive view of Global Medical REIT Inc.'s (GMRE) financial health and future prospects.
InvestingPro data reveals GMRE's Market Cap stands at 620.56M USD, with an adjusted P/E Ratio of 115.6 as of Q3 2023. The company's Revenue for the last twelve months as of Q3 2023 amounts to 144.39M USD, showcasing a growth of 9.96%. Interestingly, the Dividend Yield as of the end of 2023 is quite significant at 9.13%.
InvestingPro Tips highlight that GMRE exhibits high earnings quality, with free cash flow exceeding net income. This is a positive sign, indicating the company's ability to generate cash above its reported net income. Additionally, the company pays a substantial dividend to shareholders, which is supported by the high Dividend Yield data.
Moreover, GMRE's liquid assets exceed short-term obligations, suggesting strong liquidity. This is a crucial aspect for investors, as it means the company is well-positioned to meet any immediate financial obligations.
For those interested in more detailed insights, InvestingPro offers a plethora of additional tips and metrics that can further assist in making informed investment decisions.
Full transcript - GMRE Q3 2023:
Operator: Greetings, and welcome to the Global Medical REIT Third Quarter 2023 Earnings Conference Call. [Operator Instructions]. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Steve, Investor Relations. Thank you, sir. You may begin.
Stephen Swett: Thank you. Good morning, everyone, and welcome to Global Medical REIT's Third Quarter 2023 Earnings Conference Call. On the call today are Jeff Busch, Chief Executive Officer; Alfonzo Leon, Chief Investment Officer; and Bob Kiernan, Chief Financial Officer. Please note the use of forward-looking statements by the company on this conference call. Statements made on this call may include statements which are not historical facts and are considered forward-looking. The company intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and is making the statement for purpose of complying with those safe harbor provisions. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond the company's control, including, without limitation, those contained in the company's 10-K for the year ended December 31, 2022, and its other SEC filings. The company assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, on this call, the company may refer to certain non-GAAP financial measures such as funds from operations, adjusted funds from operations, EBITDAre and adjusted EBITDAre. You can find a tabular reconciliation of these non-GAAP financial measures to the most currently comparable GAAP numbers in the company's earnings release and in filings with the SEC. Additional information may be found on the Investor Relations page of the company's website at www.globalmedicalreit.com. I would now like to turn the call over to Jeff Busch, Chief Executive Officer of Global Medical REIT. Jeff?
Jeffery Busch: Thank you, Steve. Good morning, and thank you for joining our third quarter 2023 earnings call. Our high-quality portfolio continues to produce strong and consistent results with portfolio occupancy at the end of the quarter of 96.7% and a weighted average lease term of 5.7 years. During the quarter, we sold a medical office building located in North Charleston, South Carolina at a 5.3% cap rate, receiving gross proceeds of $10.1 million and resulting in a gain of $2.3 million. Year-to-date, we have generated more than $80 million of gross proceeds from 3 dispositions using the net proceeds to pay down our variable rate debt resulting in a leverage ratio at the quarter end of 44.2% and reducing our ratio of variable rate debt to just under 11% and of our total indebtedness, including the $2.3 million gain from the sale of the North Charleston property, our net income attributable to common shareholders for the third quarter of 2023 was $3.1 million or $0.05 per share compared to $8.1 million which included $6.8 million gain from the sale of a property or $0.12 per share in the third quarter of 2022. FFO in the third quarter was $0.22 per share and unit, down $0.01 from the third quarter of last year. And AFFO was $0.23 per share and unit down $0.02 from the third quarter of last year. The primary reason for the decline in both FFO and AFFO was an increase in interest cost in the current quarter due to the elevated interest rate environment. During the quarter, although we had no acquisition, we continue to dedicate time and resources to identifying properties that align with our investment criteria and prudent underwriting standards. As we start to see more attractive pricing in the market, we will remain disciplined in our approach, focusing on high-quality assets that would be accretive to our earnings. Overall, I am pleased with our third quarter results and want to thank the entire team for their hard work and contributions to our results. With that, I turn the call over to Alfonzo to discuss our disposition activity and our current acquisition market conditions in more detail.
Alfonzo Leon: Thank you, Jeff. The transaction market for our target assets continues to be restricted with a number of higher interest rates and a wide bid-ask spread. We continue to see a number of opportunities, but we are disciplined about our investment process. Although we did not complete any acquisitions in this quarter, we continue to actively engage with a wide range of physician groups, brokers and corporate sellers. We are ready to seize potential opportunities particularly as some owners may consider selling if they face challenges when refinancing their mortgages. The market continues to evolve, and we are tracking it closely. As Jeff mentioned, in the third quarter, we sold a medical office building located in North Charleston, South Carolina at a cap rate of 5.3%, receiving gross proceeds of $10.1 million. With this sale, we have now completed 3 dispositions for a total of 6 properties that have generated $80.5 million in aggregate gross proceeds at a weighted average cap rate of 6.3%, resulting in an aggregate gain of $15.6 million. We were very pleased with the level of investor interest that we experienced in executing these dispositions. Given the continued uncertainty with the equity markets, and their influence on current equity valuations and our cost of capital, we are faced with challenges in predicting when our acquisition activity will resume. Nevertheless, we are actively involved in the market and are prepared to ramp up our acquisition efforts once markets normalize and cap rates generally provide an attractive spread relative to our cost of capital. During this time, we have the benefit of staying patient due to the stability of our diversified portfolio of high-quality medical office properties, along with our ample liquidity. As always, we will continue to seek opportunities that align with our investment strategy and capital structure and will leverage our competitive advantages, such as scale, access to capital and the potential use of OP unit deal structures when applicable. With this approach, we remain confident in our capacity to navigate current market challenges and to capitalize on opportunities as they arise. The investment landscape has improved significantly in 2023 shifting from a seller's market to a buyer's market, and we expect leverage to continue improving for buyers with access to capital. I'd like now to turn the call over to Bob to discuss our financial results. Bob?
Robert Kiernan: Thank you, Alfonzo. GMRE's portfolio continues to produce consistent and solid results, demonstrating its resilient foundation. At the end of the third quarter, our portfolio consisted of gross investments in real estate of $1.4 billion and included $4.7 million of total leasable square feet, 96.7% occupancy 5.7 years of weighted average lease term, 4.2x rent coverage with 2.1% weighted average contractual rent escalations. In the third quarter, our total revenues increased slightly compared to last year to $35.5 million, driven primarily by the timing of our 2022 acquisitions and the performance of our portfolio, partially offset by the impact of property dispositions. On a same-store basis, excluding cash-based leases, our third quarter revenues were up $900,000 or 3.4% compared to the third quarter of 2022, driven by our rent estimators as well as new leases. Our total expenses for the third quarter were $33 million compared to $32.1 million in the prior year quarter. This increase was primarily due to increased operating expenses and G&A expenses. Our interest expense in the third quarter was $7.2 million compared to $7 million in the comparable quarter of last year as the deleveraging we have accomplished so far in 2023 and it's incorporated into our results despite the continued high interest rate environment. In particular, note that beginning in early August, our credit facility pricing improved by 15 basis points as a result of our reduced leverage. In addition, in early August, certain of our forward starting interest rate swaps became effective, replacing maturity swaps, which reduced the interest cost on our $350 million term loan by 30 basis points compared to prior periods. G&A expenses in the third quarter of 2023 were $4.4 million compared to $4 million in the third quarter of 2022. Within our current quarter G&A expenses, note that our stock compensation costs of $1.2 million in the quarter and our cash G&A costs were $3.2 million. Currently, we continue to expect our G&A expenses to be in the range of $4.3 million and $4.5 million on a quarterly basis. Our operating expenses for the third quarter were $7.2 million compared to $6.7 million in the prior year quarter, with the increase in these expenses driven by the changes in our portfolio since the comparable prior year period. Note that real estate-related taxes represent the largest component of our operating expenses. Regarding these third quarter expenses, $5.3 million related to net leases where the company recognized a comparable amount of expense recovery revenue and $1.4 million related to gross leases. Net income attributable to common stockholders for the third quarter was $3.1 million or $0.05 per share compared to $8.1 million or $0.12 per share in the third quarter of 2022. Net income for the current quarter included a gain on sale of the North Charleston medical office building of $2.3 million and in the prior year included a gain on sale of $6.8 million. FFO in the third quarter was $15.3 million or $0.22 per share and unit compared to $16.2 million or $0.23 per share and unit in the third quarter of 2022. AFFO in the third quarter was $16.5 million or $0.23 per share and unit compared to $17.1 million or $0.25 per share and unit in the third quarter of 2022. Moving on to the balance sheet. As of September 30, 2023, our gross investment in real estate was $1.4 billion, which is down about $60 million from the start of the year, reflecting our disposition activity. As of September 30, 2023, we had $626 million of gross debt with a weighted average remaining term of 3.1 years. At quarter end, 89% of our total debt was fixed rate debt, our leverage ratio was 44.2% and our weighted average interest rate was 3.78%. As I mentioned, with our reduced leverage ratio, during the quarter, we lowered the SOFR margins in our credit facility by 15 basis points with SOFR margin on our revolver now at 1.35%, and our term loan margins are now at 1.30%. Lastly, the current unutilized borrowing capacity under the credit facility is $318 million. We did not issue any shares of common stock under our ATM program during the quarter or subsequent to quarter end. With respect to our lease expirations, based on activity to date currently, we are projecting that we'll retain 80% of the 363,000 square feet that we've noted as expiring this year and 86% of the related expiring ABR. We expect to end the year with occupancy to approximately 96.5%. Our outlook regarding 2024 lease expirations is very good and in general, consistent with our experience on 2023 lease expirations. Regarding capital expenditures on the portfolio through September 30, our cash spend was approximately $5.8 million. Currently, we're projecting additional expenditures of approximately $2 million related to building and site improvements and $1 million in tenant improvement primarily associated with lease renewals and lease up, we expect to be completed during the remainder of 2023. In conclusion, as we look to the balance of the year, with our strong portfolio and ample liquidity available to us during these uncertain market conditions, we believe we are well positioned to restart our growth strategy as conditions normalize and look forward to sharing our progress in the quarters to come. This concludes our prepared remarks. Operator, please open the call for questions.
Operator: [Operator Instructions]. Our first question comes from Austin Wurschmidt with KeyBanc Capital Markets.
Austin Wurschmidt: Alfonzo, can you provide some additional detail on just the volume of opportunities or breadth of conversations that you're having that on deals that kind of meet that underwriting criteria. And you mentioned the bid-ask spread remains wide, but has it narrowed at all from the last 60 to 90 days or so?
Alfonzo Leon: Sure. So we've -- we see about 30, 40 deals a month, a lot of it doesn't make sense. The bid-ask spread has improved over the year. It started pretty wide at the beginning of 2023 and has narrowed quite a bit. There's been capitulation from sellers started the year with a lot of reluctance to accept that there was a pretty significant change in pricing. But there's increasing acknowledgment that pricing has changed by a pretty meaningful amount. And there's buyers who are coming -- sorry, sellers who are coming to market now are much more realistic. . What's also happened is what's coming to market, the quality is -- has varied month by month. There was a stretch where there wasn't that -- the quality had been lower than average. That's changing as well. I think there's some of the sellers coming to market have to sell for a variety of reasons. Some of it include financing that's running out of term. Some of it is just developers who had product that they want to sell despite the increase in pricing. There's a lot of reasons why people are still coming to market despite the high increase in cap rates. So the bid-ask spread has improved quite a bit. From our vantage point, there hasn't really been very compelling deals yet for us to move forward. And that's irregardless of where our stock price is like there just hasn't really been anything super compelling. It's getting better. I mean there's beginning to be opportunities that are catching our eyes that seem pretty interesting. And so the trend is moving in the right direction. But for the past several months, like what's -- what we've seen and what's been in the market hasn't been that compelling.
Austin Wurschmidt: So as a follow-up, I guess, as it relates to that wall of -- or as you're saying, sellers are kind of facing upcoming maturities and seem like they're more willing to negotiate. I mean, is there sort of a period or a wall of maturities that you're looking towards you think you can see an even greater increase in opportunities? Are you expecting more of a continuous drip of deals into next year?
Alfonzo Leon: Sure. Yes. So definitely, any offering that has a short wall and that depends on location, quality of the building, the rent roll, but anything with, I'd say, less than 3 years of wall, is very hard to finance right now unless it just has a very unique location. And so any offering that has a short walled is not finding many bids and in some cases, no bids. And so there is opportunities to go in there and get properties at a pretty significant discount to where they were a year ago. And so we've been looking at a fair number of those opportunities. But to date, there hasn't really been any offering yet that has the right quality mix that has the right risk profile that has the right rent roll. And for the ones that do have a good profile that do have a good rent roll that are attractive buildings, there's still a pretty wide bid-ask spread. And so for 2023, I'd say investors have been rewarded for being on the sidelines. There have been better deals had now than they were at the beginning of the year. And I think there's acknowledgment by people in the market that you were not rewarded for getting into the market in the first half of the year. I think that's starting to change. And I think a lot of it has to do -- a lot of it is hinged on expectations for what the Fed is going to do and whether or not it's going to -- what's in store for 2024. But I think we are approaching a point where investors are going to start feeling more comfortable pushing back into the market more meaningfully?
Austin Wurschmidt: Would you be willing to take on some more limited , I guess, for the right discount that leasing risk for the right discount?
Alfonzo Leon: Yes. And a lot of that is hinged on our underwriting of the renewal probability. And so there have been some opportunities that we've pursued in the past where that was the case where it was a short walled, but we felt very strongly that the renewal was going to be very, very high, just given the context, given the property, given the tendency. And so yes, if there's a property that has the right quality mix, the right rent roll and very high renewal probabilities then with a sufficient discount, we would pursue.
Operator: Our next question comes from Juan Sanabria with BMO Capital Markets.
Juan Sanabria: Just curious what's left on the disposition side that you guys are targeting? I believe you were initially thinking maybe $90 million. So I just wanted to confirm if that is still contemplated as you move into to '24 or how you're thinking about disposition/deleveraging?
Jeffery Busch: We're -- the market has changed a bit since we sold. We got really good pricing -- so we're looking around to possibly sell some more, but I'm pretty doubtful that we'll get the right pricing that we got before. So we're more likely to stay at $80 million and $90 million.
Juan Sanabria: Okay. And then just curious on the acquisitions where you're feeling maybe a little bit more comfortable that pricing has adjusted from sellers' expectations from higher rates, et cetera. What kind of cap rates or yields are you looking to target for acquisitions? And is it more skewed towards multi or single tenant deals. If you could just give us a little color of where you feel most comfortable if and when the acquisition kind of restarts?
Jeffery Busch: Okay. Number one rule before we do anything, it has to be accretive and we have to like the property, and it has to be the same quality of property that's given us a 97% occupancy in the last periods of time. . So multiple tenants can be very interesting because it's not that competitive because a lot of groups just don't have the capability like we do of managing the multiple tenants. Single tenant, it's more competitive, but I expect -- I'm hoping to get in the 8s, maybe in the 9s. It really depends on what the cost of debt is at the time that we do come in, but the #1 criteria we have is it has to be decently accretive to the portfolio. And the second element is we're in the process of reducing our leverage, so we'd be using basically 60% equity and 40% debt on average. So there's a process that we're looking -- so there's several criteria we have to work on, but it definitely has to be accretive.
Juan Sanabria: Great. And then Bob, you gave some general parameters, I think I think about '24. So how should we think about occupancy over the next kind of 5 quarters or so, I think you had expect maybe some nonrenewals in the fourth quarter, if you can correct me if I'm wrong there, and just expectations into '24 for upcoming maturities on leases.
Robert Kiernan: Yes, Juan. So yes, we expect our fourth quarter occupancy to be right around 96.5% right in that -- in that ballpark. And then as we look ahead to 2024, we're looking at our renewals to be really tracking very similarly to how we did this year. Somewhere in that 80% to 85% type range on both square feet and on ABR as we look at 2024 right now. And so what that would be from an overall occupancy, it would be in this -- if it ticked down, it depends on absorption -- maybe as a floor, think of 96%, a high 95% as maybe where it could trend on the low side. But I think we feel very confident in how we are trending for 2024.
Operator: Our next question comes from Rob Stevenson with Janney.
Robert Stevenson: Just to follow up on that last question. Can you talk about how much demand you're seeing for incremental space today? I mean relative to the last few years, is it harder, easier about the same in terms of backfilling vacancy and the demand for expansions from tenants?
Jeffery Busch: Yes, I would say we keep back filling vacancy. It may even be a little bit better than last year. We're finding tenants, we feel in some challenging ones. You always have some 1 -- smaller ones that have been challenging, they have been sitting for a couple of years. We solved that this year. I'm encouraged that medical office is growing. I mean we're not doing much with the expansion. I think it's because cost of capital right now. But we are seeing that a lot of our long term, they were small. But longer term, we've been finding that we're leasing them up. So I'm very encouraged about the leasing. And going forward, the same thing. We hear of somebody who is moving out and then we hear relatively quickly a replacement. So the market seems to be okay in that terms. If we do in 2024 lose some tenants, I expect that we'll fill them up relatively quickly.
Robert Stevenson: Okay. That's helpful. And I think you might have a small Genesis Care asset. Has that been resolved as of yet? Or is that process still ongoing?
Robert Kiernan: We really didn't have any significant exposure, Rob, to Genesis. I mean whatever we did have, I think, was something that was moving out in the fourth quarter. And so nothing -- there's really nothing material from an impact perspective on our portfolio.
Robert Stevenson: Okay. And I guess, Bob, that leads me to -- other than the impact of any acquisitions, dispositions and higher rates, is there anything else that's either carrying over from the third quarter positively or negatively earnings-wise or alternatively going away that we should be thinking about when factoring in into our models?
Robert Kiernan: No, nothing significant, really, if I bridge the third to the fourth quarter. The third quarter was very consistent if you kind of think back from a trend perspective after the dispositions, flow, I think, very predictably. And I don't think there's anything really too unusual that I mentioned, the occupancy expectations for the end of the year. But otherwise, the trends relative to our -- to where we are going from a rent perspective, from an interest perspective is teed up, and I think really nothing unusual expected.
Robert Stevenson: Okay. And when during the quarter did the sale happen, how much of the NOI off of that, did you wind up recognizing in the third quarter?
Robert Kiernan: Just 1 month of that -- it was really...
Operator: Our next question comes from Alex Kubicek with Baird.
Alexander Kubicek: The first one is relating to that 90 basis points of expiring leases. You mentioned that 80% of the space will be renewed and 86% of ABR, curious what kind of lease escalators you're able to get with those tenants today?
Jeffery Busch: We've been averaging 2.5% on our portfolio with lease escalators. Remember most of our triple net absolute net. Most of our properties are triple net absolute net, but they're really paying the expenses of the inflationary expenses -- so we get 2.5% beyond that. .
Alexander Kubicek: Is that 2.5% changed at all from the beginning of the year to now?
Jeffery Busch: Yes. Actually, it's been going up I mean our overall portfolio was running around 2.1%, and we're seeing now about 2.5% in the renewal type of piece.
Alexander Kubicek: Second question is, how are your tenants performing? And are there any change to the watch list?
Robert Kiernan: Yes, there's been no -- yes, no significant changes relative to tender performance. We've had a real solid tenant performance over the last year. So nothing notable.
Alexander Kubicek: All right. Good to hear -- last one for me is how much of the investment pipeline comes from new relationships versus existing ones?
Alfonzo Leon: I don't have a precise data on that. I mean it's pretty varied. And we cast a pretty wide net -- but I'd say, on average, about 1/3 of what we see is from new sources.
Operator: Our next question comes from Bryan Maher with B. Riley Securities.
Bryan Maher: Just two quick ones for me. Maybe for Jeff or Bob. On the dividend, and I asked this before, prior quarters that [indiscernible] out there, again, with the elevated payout ratio relative to FFO or FAD -- we know it improves organically in 2024 and 2025. And I suspect that if you make accretive acquisitions that only gets better, but not worse, but we get a lot of questions from shareholders and advisers that, that dividend is safe at current levels. Is it your thought that the Board holds the line at the $0.21 dividend?
Jeffery Busch: Yes. This is Jeff, and I'm also on the Board. So I'm in that discussion Yes. Ever -- the Board does not want to change the dividend. I wouldn't expect it going up either, but -- for the immediate future. We feel safe with the dividend. We think we sort of hit a bottom here. We sold out a bunch of properties brought down our variables in debt we still get our increases every year and our increases every year are now exceeding what the additional debt costs could possibly be unless something gets too wild. But we think we're okay with the dividend. And I totally expect so there's no move to do anything with it.
Bryan Maher: Great. And just one for me, maybe for Alfonzo, when you're talking to potential sellers, do they seem to continue to be somewhat receptive to taking OP units? Has that tone changed at all? What's going on in that regard?
Alfonzo Leon: Sure. With the OP, it's always been curious to me. It really is hard to predict. I find it curious that we've had success in California with OPs, I think that's -- there's a specific state context that might be a reason for that. It also is highly dependent on the specific like estate planning of the physicians. And for some physicians, by the time we were talking to them, they were already thinking about it and had done a lot of homework about OP unit shares, up REITs, down REITs. And so we were -- we didn't -- there wasn't much that we had to explain or walk through. I mean, they pretty much knew what they wanted. And so it's really hard to predict. And we make a point of mentioning it whenever we think it makes sense. But it's not a product that a lot of people are familiar with are comfortable with and want to move forward with an exchange for their properties.
Operator: We have reached the end of our question-and-answer session. This concludes today's conference. Thank you for your participation. You may disconnect your lines at this time.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.